Curator Dashboard

Exploratory Gene Association Networks (EGAN) is a software tool that allows a bench biologist to visualize and interpret the results of high-throughput exploratory assays in an interactive hypergraph of genes, relationships (protein-protein interactions, literature co-occurrence, etc.) and meta-data (annotation, signaling pathways, etc.). EGAN provides comprehensive, automated calculation of meta-data coincidence (over-representation, enrichment) for user- and assay-defined gene lists, and provides direct links to web resources and literature (NCBI Entrez Gene, PubMed, KEGG, Gene Ontology, iHOP, Google, etc.). EGAN functions as a module for exploratory investigation of analysis results from multiple high-throughput assay technologies, including but not limited to: * Transcriptomics via expression microarrays or RNA-Seq * Genomics via SNP GWAS or array CGH * Proteomics via MS/MS peptide identifications * Epigenomics via DNA methylation, ChIP-on-Chip or ChIP-Seq * In-silico analysis of sequences or literature EGAN has been built using Cytoscape libraries for graph visualization and layout, and is comparable to DAVID, GSEA, Ingenuity IPA and Ariadne Pathway Studio. There are pre-collated EGAN networks available for human (Homo sapiens), mouse (Mus musculus), rat (Rattus norvegicus), chicken (Gallus gallus), zebrafish (Danio rerio), fruit fly (Drosophila melanogaster), nematode (Caenorhabditis elegans), mouse-ear cress (Arabidopsis thaliana), rice (Oryza sativa) and brewer's yeast (Saccharomyces cerevisiae). There is now an EGAN module available for GenePattern (human-only). Platform: Windows compatible, Mac OS X compatible, Linux compatible

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Tk-GO is a GUI wrapping the basic functions of the GO AppHandle library from BDGP. GO terms are presented in an explorer-like browser, and behavior can be configured by altering Perl scripts. All available documentation is included in the download. Tk-GO uses the GO database (connects directly to the BDGP database by default) but is user-configurable. Platform: Windows compatible, Mac OS X compatible, Linux compatible, Unix compatible

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Onto-Express is a web-based tool in the Onto-Tools suite that performs automated function profiling for a list of differentially expressed genes. However, Onto-Express does not support functional profiling for the organisms that do not have annotations in public domain, or use of custom (i.e. user-defined) ontologies. This limitation is also true for most of the other existing tools for functional profiling, which means that researchers working with uncommon organisms and/or new annotations or ontologies may be forced to construct such profiles manually. Onto-Express To Go (OE2GO) is a new tool added to the Onto-Tools ensemble to address these issues. OE2GO is built on top of OE to leverage its existing functionality. In OE2GO, the users now have an option to use either the Onto-Tools database as a source of functional annotations or provide their own annotations in a separate file. Currently, OE2GO supports annotation file in the Gene Ontology format. Platform: Online tool, Windows compatible, Mac OS X compatible, Linux compatible, Unix compatible

• Resource
• SciCrunch
• 15 years ago - by Anonymous

We aim to facilitate the pathway for access, storage, use and transfer of human organs, cells and tissue between clinical centers within UCL Partners, academic groups in UCL, other universities, hospitals, medical researcher and biotechnology companies, to enhance the ability for researchers to access the materials they need. Alongside this, researchers will be able to exchange information and access guides on regulatory, ethics and practical issues concerning access, transfer and use of this type of material. These guides will be video and documents format, based on talks at organized events given by experts in the relevant fields. All of this information will be accessible on a website that seeks to link groups within UCL and attract attention from the wider world through social media and expansion of existing contacts. Our vision is to develop a centralized human tissue provision and utilization service for academic and commercial researchers UCL has the highest concentration of biomedical researchers in Europe. As part of this, UCL has numerous licensed biobanks and is associated with many research intensive hospitals in North London. The role of a biobank is to prepare and hold human tissue samples in for use by medical researchers to help delivery new treatments. Hospitals can also provide human tissue for research by utilizing waste human tissue taken as part of surgery or diagnostic procedures, but is normally incinerated. The researchers using the human tissue could be working within academic laboratories in UK universities and institutions or as part of commercial companies. Researchers currently cannot easily access human tissue to meet the demands of their research, often due to the long ethical, regulatory and contractual processes. However, with the enormous UCL biobanking and research Hospital resources, UCL could be a leading academic institution in providing human tissue for medical research within the UK and internationally. Our vision is to develop a centralized human tissue provision and utilization service for academic and commercial researchers. This relies on creating an overarching infrastructure, to consolidate information on disparate human tissue resources around UCL, and (where possible) gain centralized ethical and regulatory and contractual approval for use of the tissue. Funding the infrastructure will rely on a cost recovery model for a per sample basis. As a result the time needed to obtain tissue for research will be dramatically reduced, whilst providing a simple costing model for obtaining human tissue. This will make human tissue procurement much more efficient for end users.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

The Brain Molecular Anatomy Project is a trans-NIH project aimed at understanding gene expression and function in the nervous system. BMAP has two major scientific goals: # Gene discovery: to catalog of all the genes expressed in the nervous system, under both normal and abnormal conditions. # Gene expression analysis: to monitor gene expression patterns in the nervous system as a function of cell type, anatomical location, developmental stage, and physiological state, and thus gain insight into gene function. In pursuit of these goals, BMAP has launched several initiatives to provide resources and funding opportunities for the scientific community. These include several Requests for Applications and Requests for Proposals, descriptions of which can be found in this Web site. BMAP is also in the process of establishing physical and electronic resources for the community, including repositories of cDNA clones for nervous system genes, and databases of gene expression information for the nervous system. Most of the BMAP initiatives so far have focused on the mouse as a model species because of the ease of experimental and genetic manipulation of this organism, and because many models of human disease are available in the mouse. However, research in humans, other mammalian species, non-mammalian vertebrates, and invertebrates is also being funded through BMAP. For the convenience of interested investigators, we have established this Web site as a central information resource, focusing on major NIH-sponsored funding opportunities, initiatives, genomic resources available to the research community, courses and scientific meetings related to BMAP initiatives, and selected reports and publications. When appropriate, we will also post initiatives not directly sponsored by BMAP, but which are deemed relevant to its goals. Posting decisions are made by the Trans-NIH BMAP Committee

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Database of blood-brain barrier properties of peptides including structure, method, responses, physicochemical properties and related literature. The database is linked to a manuscript entitled Brainpeps: the blood-brain barrier peptide database, in which the BBB methods and responses are clarified and correlated to each other. Data may be submitted for addition to the database.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

My laboratory has created a family of natural product-inspired anticancer agents. We have evaluated our compounds at the Yale Center for Chemical Genomics, and they are exhibiting IC50 values in the low nM range against K562, HeLa, LnCAP, and HCT-116 lines. Their mechanism of action is unknown, although the natural products have been shown to cleave DNA. An evaluation of the natural products at the NCI has shown that they have a toxicity profile that is distinct from other known DNA damaging agents. We can readily access gram-quantities of these agents for further studies. We are looking for researchers who might find these compounds useful in medicinal applications, for example, for treatment of a specific cancer. We are capable of synthesizing new analogs, such as those incorporating a specific recognition or targeting element, and would be excited to pursue this avenue of research.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Open tools to support data management for biological light microscopy produced by a multi-site collaborative effort among academic laboratories and a number of commercial entities. Designed to interact with existing commercial software, all OME formats and software are free, and all OME source code is available under the GNU General public license or through commercial license from Glencoe Software. OME is developed as a joint project between research-active laboratories at the Dundee, NIA Baltimore, and Harvard Medical School and LOCI. In addition, OME has active collaborations with many imaging and informatics groups. While many other applications could use OME''s architecture and design, their specific implementation is focused on biological and biomedical imaging. Those interested in applying OME''s technology to other applications should contact the developers. OME work is divided into several different standards and software projects: * Bio-Formats: A Java-based library for reading and writing over 90 microscopy file formats. * OMERO Software: The Java-based OMERO software project, which currently includes tools for storing, visualizing, managing, and annotating microscopic images and metadata. * OME-XML & OME-TIFF: The OME-XML and OME-TIFF file format specifications, which are open file formats for sharing microscope image data. * OME Server: This was the original OME server project which has now ended and is a legacy product. It implements image-based analysis of cellular dynamics and image-based screening of cellular localization or phenotypes, and included a fully developed version of the 2003 version of OME-XML Schema language.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Map of neural connections in mouse brain, built on an array of transgenic mice genetically engineered to target specific cell types. In addition to the connectivity data, information about the transgenic mouse lines and genetic tracers is available. Consists of high resolution 2-D projectivity image data that can be viewed side-by-side with the associated reference atlas and other reference datasets. Enables 3-D visualization and spatial/ontological search of connectivity models through a combination of manual and informatics analyses.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

High throughput screening services to identify small molecules that can be optimized as chemical probes to study the functions of genes, cells, and biochemical pathways, along with medicinal chemistry and informatics. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. The NIH Molecular Libraries Initiative NIH is designed to discover small molecules that interact with biologically important proteins and pathways and to provide open access to the bioassay and chemical data generated by its research centers. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. As these HTS Technologies were not previously available to the public sector, many investigators may not be familiar with the components and requirements of high throughput screening. A key challenge is to identify small molecules effective at modulating a given biological process or disease state. The Molecular Libraries Roadmap, through one of its components, the Molecular Libraries Probe Production Centers Network (MLPCN), offers biomedical researchers access to the large-scale screening capacity, along with medicinal chemistry and informatics necessary to identify chemical probes to study the functions of genes, cells, and biochemical pathways. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. There are two kinds of data that are available to the scientific community through a dedicated database: Chemical Compounds and Bioassay Results (NCBI). Various types of data, including informative records on substances, compound structures, and biologically active properties of small molecules are housed respectively within PubChem''''s three primary databases: PCSubstance, PCCompound, and PCBioAssay. To date, PubChem contains over 11 million substance records, details about approximately 5.5 million unique compound structures with links to bioassay descriptions, relevant literature, references, and assay data points and over 250 bioassays, a good percentage of which were contributed by the pilot phase of the MLP. The deposition will continue during the current MLPCN phase. NIH anticipates that these projects will also facilitate the development of new drugs, by providing early stage chemical compounds that will enable researchers in the public and private sectors to validate new drug targets, which could then move into the drug-development pipeline. This is particularly true for rare diseases, which may not be attractive for development by the private sector. Funding opportunities are available through the site.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Publications put out by the National Institute of Mental Health. Publications are available by topic: Disorders: * Attention Deficit Hyperactivity Disorder (ADHD) * Anxiety Disorders * Autism * Bipolar Disorder * Borderline Personality Disorder * Depression * Eating Disorders * Generalized Anxiety Disorder * Obsessive-Compulsive Disorder (OCD) * Panic Disorder * Post-Traumatic Stress Disorder * Schizophrenia * Social Phobia Populations * Older Adults * Men''s Mental Health * Women''s Mental Health * Children and Adolescents Research * Basic Research * Clinical Research and Trials * Research Funding * Mental Health Services Research Other * Coping with Traumatic Events * Genetics * HIV/AIDS * Imaging * Medications * NIMH * Prevention * Statistics * Suicide Prevention * Treatments

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Merging Two Gene Expression Studies via Cross Platform Normalization.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A long-term outpatient study designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. This study has been completed. (2005) STEP-BD is evaluating all the best-practice treatment options used for bipolar disorder: mood-stabilizing medications, antidepressants, atypical antipsychotics, and psychosocial interventions - or talk therapies - including Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythm Therapy, and Collaborative Care (psychoeducation). There are two kinds of treatment pathways in STEP-BD, and participants may have the opportunity to take part in both. The medications and psychosocial interventions provided in these pathways are considered among the best choices of treatment for bipolar disorder in everyday clinical practice. In the Best Practice Pathway, participants are followed by a STEP-BD certified doctor and all treatment choices are individualized. Everyone enrolled in STEP-BD may participate in this pathway. Participants and their doctors work together to decide on the best treatment plans and to change these plans if needed. Also, anyone who wishes to stay on his or her current treatment upon entering STEP-BD may do so in this pathway. Adolescents and adults age 15 years and older may participate in the Best Practice Pathway. For adults age 18 and older, another way to participate is in the STEP-BD Randomized Care Pathways. Depending on their symptoms, participants may be offered treatment in one or more of these pathways during the course of the study. The participants remain on mood-stabilizing medication. However, because doctors are uncertain which of several treatment strategies work best for bipolar disorder, another medication and/or talk therapy may be added. Each Randomized Care Pathway involves a different set of these additional treatments. Unlike in the Best Practice Pathway, the participants in the Randomized Care Pathways are randomly assigned to treatments. Also, in some cases, neither the participant nor the doctor will be told which of the different medications is being added. This is called a double-blind study and is done so that the medication effects can be evaluated objectively, without any unintended bias that may come from knowing what has been assigned. Participants will not be assigned medications that they have had bad reactions to in the past, that they are strongly opposed to, or that the doctor feels are unsuitable for them. The medication(s) participants may be randomly assigned to in the Randomized Care Pathways are free of charge. There are other treatment options for participants if they do not respond well to the treatment assigned to them. Also, participants may return to the Best Practice Pathway at any time. About 1,500 individuals will be enrolled in at least one Randomized Care Pathway during their period of participation in STEP-BD. It is important to note that STEP-BD provides continuity of care. For example, if a participant starts out in the Best Practice Pathway and later chooses to enter one of the Randomized Care Pathways, he or she continues with the same STEP-BD doctor and treatment team. Then, after completing the Randomized Care Pathway, the participant may return to the Best Practice Pathway for ongoing, individually-tailored treatment. Follow the link to view study info at Clinicaltrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00012558?order=1

• Resource
• SciCrunch
• 15 years ago - by Anonymous

This is the second in a series of modules on neuroscience and psychiatry. This module describes neuroscience research on animal models of fear that informed human studies of fear/safety, anxiety and anxiety disorders. This model helps shed light on the symptoms of PTSD and lead to the development of a novel treatment that has been successful in research studies for several anxiety disorders.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

This comprehensive free collection of multimedia resources and inquiry-based activities tied to the National Science Education Standards help teachers and students learn about the structure, function and cognitive aspects of the human brain. The packet includes a teacher's manual, student manual, DVD of videos, and a CDROM of accompanying materials.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Blog by the NIMH Director, Thomas R. Insel, M.D. Users may sort posts by topic and/or subsribe to the RSS Feed, http://www.nimh.nih.gov/site-info/feed-directors-blog.atom

• Resource
• SciCrunch
• 15 years ago - by Anonymous

The mission of the Spinal Muscular Atrophy Foundation is to accelerate the development of a treatment for SMA, the number one genetic killer of infants and toddlers. To help speed the realization of a treatment or cure, the SMA Foundation is committed to: Developing private sector involvement in SMA drug development by fostering alliances between academia, government, and pharmaceutical and biotechnology companies Increasing government funding and support through targeted efforts to increase Congressional and NIH awareness Raising awareness of SMA among government leaders, members of the pharmaceutical and biotechnology industries, and the public at large

• Resource
• SciCrunch
• 16 years ago - by Anonymous

Dataset from an investigation of biochemical evidence of myocardial strain, oxidative stress, and cardiomyocyte injury in 55 acute KD subjects (30 with paired convalescent samples), 54 febrile control (FC), and 50 healthy control (HC) children by measuring concentrations of cardiovascular biomarkers. NT-proBNP and sST2 were elevated in acute KD subjects and correlated with impaired myocardial relaxation. These findings, combined with elevated levels of cTnI, suggest that both cardiomyocyte stress and cell death are associated with myocardial inflammation in acute KD.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Software programs that are extensions of the LINKAGE programs that allow the disease phenotype to be under the control of disease two loci. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Brain tissue donation program at the UT Southwestern Memory Clinic that aims to utilize these contributions for research on Alzheimer's. Diagnosis of Alzheimer's disease or other dementias are made through autopsy, the results of which are available to family members.

• Resource
• SciCrunch
• 15 years ago - by Anonymous